ALK and non-small cell lung carcinoma: As a first-line treatment, Nivo-Ipi combination therapy is extensively utilized for advanced NSCLC in patients without targetable genetic alterations in the epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK).